Showing 2231-2240 of 2652 results for "".
- Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officerhttps://modernod.com/news/outlook-therapeutics-appoints-c-russell-trenary-iii-as-president-and-chief-executive-officer/2479350/Outlook Therapeutics announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member o
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- GenSight Biologics Reports Topline Results From REFLECT Phase 3 Trial, Confirming Lumevoq Efficacyhttps://modernod.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/GenSight Biologics reported key efficacy and safety findings at 1.5 years (78 weeks) post-treatment in the REFLECT phase 3 clinical trial for Lumevoq. The results show better visual acuity improvements from bilateral intravitreal injections of the gene therapy compared to a unilateral injection.<
- William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directorshttps://modernod.com/news/william-j-link-phd-named-chairman-of-allegro-ophthalmics-board-of-directors/2479313/Allegro Ophthalmics announced that William J. Link, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance. “I am thrilled that Bill has agreed to serve as our board chairman and pleased to promote Stephanie as VP of
- Market Scope: Ophthalmic Laser Market Expected to Total $376.4 Million in 2021https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-376-4-million-in-2021/2479296/Global revenue for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total over $376.4 million in 2021 and grow at a compound annual rate of 2.4 percent from 2021 to 2026, according to Market Scope estimates. Factor
- Randy Jackson, Patient Advocates to Share Stories of Managing Eye Health While Thriving With Diabetes During Live Virtual Eventhttps://modernod.com/news/randy-jackson-patient-advocates-to-share-stories-of-managing-eye-health-while-thriving-with-diabetes-during-live-virtual-event/2479286/“Focus on Diabetes,” a multi-year eye health initiative with the American Diabetes Association (ADA), VSP Vision Care, and Regeneron, will host a virtual live event, “The Real Stories Behind our Vision,” featuring Grammy-winning musician, producer Randy Jackson. Mr.
- Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directorshttps://modernod.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018. “We a
- High Caffeine Consumption May Be Associated With Increased Risk of Glaucomahttps://modernod.com/news/high-caffeine-consumption-may-be-associated-with-increased-risk-of-blinding-eye-disease/2479268/Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure, according to an international multicenter study. The research led by the Icahn School of Medicine at Mount Sinai is the first to demonst
- AcuFocus Appoints Industry Leader John Garland as Global Vice President of Saleshttps://modernod.com/news/acufocus-appoints-industry-leader-john-garland-as-global-vice-president-of-sales/2479257/AcuFocus announced that it has appointed John Garland as its Global Vice President of Sales. In his new role, he will be responsible for global sales strategy and will focus initially on building the US sales field team. Mr. Garland brings more than 30 years of experience to the position w
- Novartis Terminates Three Trials of Beovu Despite Meeting Primary Endpoint of MERLIN Trialhttps://modernod.com/news/novartis-terminates-three-trials-of-beovu-despite-meeting-primary-endpoint/2479246/Novartis reported that Beovu met its primary endpoint in the phase 3 MERLIN trial, but decided to terminate the study due to higher rates of intraocular inflammation with frequent dosing intervals. Novartis reported the first interpretable year 1 results of the MERLIN trial, a 2-year study